{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T18:28:06Z","timestamp":1792261686316,"version":"4.4.0"},"reference-count":138,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"vor","delay-in-days":37,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101134","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T16:35:21Z","timestamp":1770482121000},"page":"101134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Treatment of ER-positive breast cancer with FDA-approved aromatase inhibitors"],"prefix":"10.1016","volume":"47","author":[{"given":"Nayoung","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8738-2117","authenticated-orcid":false,"given":"Kiven Erique","family":"Lukong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101134_bib0001","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.gendis.2018.05.001","article-title":"Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis","volume":"5","author":"Feng","year":"2018","journal-title":"Genes. Dis."},{"key":"10.1016\/j.ctarc.2026.101134_bib0002","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1172\/JCI33295","article-title":"Breast cancer: origins and evolution","volume":"117","author":"Polyak","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ctarc.2026.101134_bib0003","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.7150\/ijbs.21635","article-title":"Risk factors and preventions of breast cancer","volume":"13","author":"Sun","year":"2017","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ctarc.2026.101134_bib0004","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMra031301","article-title":"Kaelin CM. Ductal carcinoma in situ of the breast","volume":"350","author":"Burstein","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101134_bib0005","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4137\/CPath.S31563","article-title":"Diversity of breast carcinoma: histological subtypes and clinical relevance","volume":"8","author":"Makki","year":"2015","journal-title":"Clin. Med. Insights. Pathol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0006","doi-asserted-by":"crossref","first-page":"955","DOI":"10.4161\/cbt.10.10.13879","article-title":"Histological, molecular and functional subtypes of breast cancers","volume":"10","author":"Malhotra","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ctarc.2026.101134_bib0007","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3348\/kjr.2018.0231","article-title":"Introduction of a new staging system of breast cancer for radiologists: an emphasis on the prognostic stage","volume":"20","author":"Koh","year":"2019","journal-title":"Korean J. Radiol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0008","first-page":"3","article-title":"Histological classification, grading, staging, and prognostic indexing of female breast cancer in an African population: a 10-year retrospective study","volume":"13","author":"Oluogun","year":"2019","journal-title":"Int. J. Health Sci. (Qassim)"},{"key":"10.1016\/j.ctarc.2026.101134_bib0009","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.soc.2017.08.005","article-title":"Molecular subtypes and local-regional control of breast cancer","volume":"27","author":"Fragomeni","year":"2018","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"10.1016\/j.ctarc.2026.101134_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00428-014-1593-7","article-title":"Molecular classification of breast cancer","volume":"465","author":"Vuong","year":"2014","journal-title":"Virchows Arch."},{"key":"10.1016\/j.ctarc.2026.101134_bib0011","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/jnci\/djp082","article-title":"Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer","volume":"101","author":"Cheang","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ctarc.2026.101134_bib0012","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1200\/JCO.2009.22.8775","article-title":"Identification of subtypes in human epidermal growth factor receptor 2\u2013positive breast cancer reveals a gene signature prognostic of outcome","volume":"28","author":"Staaf","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0013","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1007\/s00432-022-04189-6","article-title":"Triple negative breast cancer: approved treatment options and their mechanisms of action","volume":"149","author":"Mandapati","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0014","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/modpathol.2010.200","article-title":"Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists","volume":"24","author":"Badve","year":"2011","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0015","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/sj.bjc.6602787","article-title":"Clinical characteristics of different histologic types of breast cancer","volume":"93","author":"Li","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101134_bib0016","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1158\/1078-0432.CCR-04-0220","article-title":"Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma","volume":"10","author":"Nielsen","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101134_bib0017","first-page":"2929","article-title":"Breast cancer intrinsic subtype classification, clinical use and future trends","volume":"5","author":"Dai","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101134_bib0018","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ctarc.2026.101134_bib0019","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ctarc.2026.101134_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/or.2025.1564642","article-title":"Treating ER-positive breast cancer: a review of the current FDA-approved SERMs and SERDs and their mechanisms of action","volume":"19","author":"Kim","year":"2025","journal-title":"Oncol. Rev."},{"key":"10.1016\/j.ctarc.2026.101134_bib0021","first-page":"2821","article-title":"ER+ metastatic breast cancer: past, present, and a prescription for an apoptosis-targeted future","volume":"9","author":"Rozeboom","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101134_bib0022","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4331\/wjbc.v6.i3.231","article-title":"Current medical treatment of estrogen receptor-positive breast cancer","volume":"6","author":"Lumachi","year":"2015","journal-title":"World J. Biol. Chem."},{"key":"10.1016\/j.ctarc.2026.101134_bib0023","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jacbts.2016.03.009","article-title":"Drugs, Devices, and the FDA: part 2: an overview of approval processes: FDA approval of medical devices","volume":"1","author":"Van Norman","year":"2016","journal-title":"JACC Basic Transl. Sci."},{"key":"10.1016\/j.ctarc.2026.101134_bib0024","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11892-017-0871-6","article-title":"The role of the FDA and regulatory approval of new devices for diabetes care","volume":"17","author":"Jazowski","year":"2017","journal-title":"Curr. Diab. Rep."},{"key":"10.1016\/j.ctarc.2026.101134_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1184472","article-title":"A review of FDA approved drugs and their formulations for the treatment of breast cancer","volume":"14","author":"Chaurasia","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0026","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41573-020-0060-1","article-title":"Publisher correction: breast cancer drug approvals by the US FDA from 1949 to 2018","volume":"19","author":"Leo","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ctarc.2026.101134_bib0027","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2016.67.1487","article-title":"Endocrine therapy for hormone receptor-positive metastatic breast cancer: american Society of Clinical Oncology Guideline","volume":"34","author":"Rugo","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0028","doi-asserted-by":"crossref","first-page":"433","DOI":"10.6004\/jnccn.2017.0044","article-title":"NCCN Guidelines insights: breast Cancer, version 1.2017","volume":"15","author":"Gradishar","year":"2017","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.ctarc.2026.101134_bib0029","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1080\/17512433.2016.1231575","article-title":"Raloxifene hydrochloride for breast cancer risk reduction in postmenopausal women","volume":"9","author":"Provinciali","year":"2016","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0030","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.3747\/co.25.3735","article-title":"Aromatase inhibitors in premenopausal women with breast cancer: the state of the art and future prospects","volume":"25","author":"Pistelli","year":"2018","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0031","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jsbmb.2011.02.001","article-title":"Aromatase, aromatase inhibitors, and breast cancer","volume":"125","author":"Chumsri","year":"2011","journal-title":"J. Steroid. Biochem. Mol. Biol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0032","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1470-2045(21)00758-0","volume":"23","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0033","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4103\/2279-042X.132704","article-title":"A comparative study of pre- and post-menopausal breast cancer: risk factors, presentation, characteristics and management","volume":"3","author":"Surakasula","year":"2014","journal-title":"J. Res. Pharm. Pract."},{"key":"10.1016\/j.ctarc.2026.101134_bib0034","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2165\/00002512-199813040-00008","article-title":"Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer","volume":"13","author":"Wiseman","year":"1998","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ctarc.2026.101134_bib0035","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1158\/0008-5472.CAN-09-3024","article-title":"Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer","volume":"70","author":"Ingle","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101134_bib0036","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1136\/bmj.309.6967.1501","article-title":"ABC of breast diseases. Metastatic breast cancer","volume":"309","author":"Leonard","year":"1994","journal-title":"BMJ"},{"key":"10.1016\/j.ctarc.2026.101134_bib0037","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2147\/TCRM.S3858","article-title":"Long-term efficacy and safety of letrozole for the adjuvant treatment of early breast cancer in postmenopausal women: a review","volume":"5","author":"Monnier","year":"2009","journal-title":"Ther. Clin. Risk. Manage"},{"key":"10.1016\/j.ctarc.2026.101134_bib0038","first-page":"551","article-title":"Clinical utility of exemestane in the treatment of breast cancer","volume":"7","author":"Zucchini","year":"2015","journal-title":"Int. J. Womens Health"},{"key":"10.1016\/j.ctarc.2026.101134_bib0039","unstructured":"Administration FUSFaD. Prescribing information for AROMASIN\u00ae (exemestane). 2024."},{"key":"10.1016\/j.ctarc.2026.101134_bib0040","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1146\/annurev.physiol.64.081601.142703","article-title":"Aromatase\u2013a brief overview","volume":"64","author":"Simpson","year":"2002","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0041","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0960-0760(03)00360-1","article-title":"Sources of estrogen and their importance","volume":"86","author":"Simpson","year":"2003","journal-title":"J. Steroid. Biochem. Mol. Biol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0042","doi-asserted-by":"crossref","first-page":"R19","DOI":"10.1530\/JME-15-0310","article-title":"Bulun SE. Aromatase expression and regulation in breast and endometrial cancer","volume":"57","author":"Zhao","year":"2016","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0043","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0960-0760(03)00359-5","article-title":"The human CYP19 (aromatase P450) gene: update on physiologic roles and genomic organization of promoters","volume":"86","author":"Bulun","year":"2003","journal-title":"J. Steroid. Biochem. Mol. Biol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0044","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.canlet.2014.04.018","article-title":"Estrogen metabolism and breast cancer","volume":"356","author":"Samavat","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ctarc.2026.101134_bib0045","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMra023246","article-title":"Aromatase inhibitors in breast cancer","volume":"348","author":"Smith","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101134_bib0046","first-page":"372","article-title":"Treatment of advanced breast cancer with aminoglutethimide\u2013response after previous tamoxifen treatment","volume":"66","author":"Bezwoda","year":"1984","journal-title":"S. Afr. Med. J."},{"key":"10.1016\/j.ctarc.2026.101134_bib0047","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/00001813-200009000-00002","article-title":"Exemestane in advanced breast cancer","volume":"11","author":"Buzdar","year":"2000","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ctarc.2026.101134_bib0048","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1210\/jcem-45-3-469","article-title":"Adrenal suppression with aminoglutethimide. I. Differential e-fects of aminoglutethimide on glucocorticoid metabolism as a rationale for use of hydrocortisone","volume":"45","author":"Santen","year":"1977","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ctarc.2026.101134_bib0049","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0960-0760(97)00072-1","article-title":"Mechanisms of the actions of aromatase inhibitors 4-hydroxyandrostenedione, fadrozole, and aminoglutethimide on aromatase in JEG-3 cell culture","volume":"63","author":"Yue","year":"1997","journal-title":"J. Steroid. Biochem. Mol. Biol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0050","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1634\/theoncologist.9-2-126","article-title":"Aromatase inhibitors for breast cancer in postmenopausal women","volume":"9","author":"Campos","year":"2004","journal-title":"Oncologist."},{"key":"10.1016\/j.ctarc.2026.101134_bib0051","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1111\/j.1742-1241.2007.01587.x","article-title":"The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer","volume":"61","author":"Fabian","year":"2007","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.ctarc.2026.101134_bib0052","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0305-7372(97)90037-2","article-title":"Aromatase inhibitors and breast cancer","volume":"23","author":"Miller","year":"1997","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ctarc.2026.101134_bib0053","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00003495-199958020-00003","article-title":"Comprehensive pharmacology and clinical efficacy of aromatase inhibitors","volume":"58","author":"Njar","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.ctarc.2026.101134_bib0054","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1517\/14740338.2010.515977","article-title":"Anastrozole","volume":"9","author":"Kelly","year":"2010","journal-title":"Expert. Opin. Drug Saf."},{"key":"10.1016\/j.ctarc.2026.101134_bib0055","unstructured":"Administration FUSFaD. Prescribing information for ARIMIDEX\u00ae (anastrozole). 2024."},{"key":"10.1016\/j.ctarc.2026.101134_bib0056","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial","volume":"9","author":"TAoiCTG","year":"2008","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0057","first-page":"291","article-title":"Long-term efficacy and safety of anastrozole for adjuvant treatment of early breast cancer in postmenopausal women","volume":"5","author":"Gangadhara","year":"2009","journal-title":"Ther. Clin. Risk. Manage"},{"key":"10.1016\/j.ctarc.2026.101134_bib0058","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2165\/00019053-200624050-00007","article-title":"Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer","volume":"24","author":"Dunn","year":"2006","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.ctarc.2026.101134_bib0059","unstructured":"Administration FUSFaD. Prescribing information for FEMARA (letrozole). 2024."},{"key":"10.1016\/j.ctarc.2026.101134_bib0060","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/JCO.18.00440","article-title":"Adjuvant Letrozole and Tamoxifen alone or sequentially for postmenopausal women with hormone receptor-positive breast cancer: long-term follow-up of the BIG 1-98 trial","volume":"37","author":"Ruhstaller","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0061","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","article-title":"A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer","volume":"349","author":"Goss","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101134_bib0062","first-page":"611","article-title":"Letrozole: advancing hormone therapy in breast cancer","volume":"8","author":"Lee","year":"2012","journal-title":"Womens Health"},{"key":"10.1016\/j.ctarc.2026.101134_bib0063","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1200\/JCO.2016.70.5640","article-title":"Long-term follow-up of the intergroup Exemestane study","volume":"35","author":"Morden","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0064","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.critrevonc.2004.02.001","article-title":"Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion","volume":"51","author":"Platet","year":"2004","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0065","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1677\/erc.1.00834","article-title":"Sex steroid-producing enzymes in human breast cancer","volume":"12","author":"Suzuki","year":"2005","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.ctarc.2026.101134_bib0066","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2165\/00003495-200868090-00007","article-title":"Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer","volume":"68","author":"Sanford","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.ctarc.2026.101134_bib0067","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/bjc.1996.94","article-title":"Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers","volume":"73","author":"Yates","year":"1996","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101134_bib0068","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/j.1365-2125.2010.03791.x","article-title":"In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole","volume":"70","author":"Kamdem","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0069","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1188\/04.CJON.87-88","article-title":"Anastrozole (Arimidex)","volume":"8","author":"Wilkinson","year":"2004","journal-title":"Clin. J. Oncol. Nurs."},{"key":"10.1016\/j.ctarc.2026.101134_bib0070","first-page":"343","article-title":"Pharmacokinetics of anti-endocrine agents","volume":"17","author":"Lonning","year":"1993","journal-title":"Cancer Surv."},{"key":"10.1016\/j.ctarc.2026.101134_bib0071","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00682745","article-title":"Arimidex: a potent and selective fourth-generation aromatase inhibitor","volume":"30","author":"Plourde","year":"1994","journal-title":"Breast. Cancer Res. Treat."},{"key":"10.1016\/j.ctarc.2026.101134_bib0072","first-page":"468S","article-title":"Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors","volume":"9","author":"Buzdar","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101134_bib0073","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2003.04.194","article-title":"Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group","volume":"21","author":"Mouridsen","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0074","doi-asserted-by":"crossref","first-page":"P79","DOI":"10.1016\/j.clpt.2004.12.193","article-title":"In vitro letrozole N-dealkylation is mainly catalyzed by human cytochrome P450 (CYP) 3A","volume":"77","author":"Desta","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ctarc.2026.101134_bib0075","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s00280-009-0935-7","article-title":"Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4\u2032-methanol-bisbenzonitrile in vitro","volume":"64","author":"Jeong","year":"2009","journal-title":"Cancer Chemother Pharmacol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0076","first-page":"673","article-title":"Letrozole: a well-tolerated and effective treatment for breast cancer","volume":"2","author":"Bundred","year":"2006","journal-title":"Womens Health"},{"issue":"Suppl 1","key":"10.1016\/j.ctarc.2026.101134_bib0077","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10549-007-9696-3","article-title":"The discovery and mechanism of action of letrozole","volume":"105","author":"Bhatnagar","year":"2007","journal-title":"Breast. Cancer Res. Treat."},{"key":"10.1016\/j.ctarc.2026.101134_bib0078","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/bdd.273","article-title":"Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients","volume":"22","author":"Pfister","year":"2001","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ctarc.2026.101134_bib0079","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0960-0760(03)00384-4","article-title":"The pharmacology of letrozole","volume":"87","author":"Haynes","year":"2003","journal-title":"J. Steroid. Biochem. Mol. Biol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0080","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/0960-0760(90)90460-3","article-title":"Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor","volume":"37","author":"Bhatnagar","year":"1990","journal-title":"J. Steroid. Biochem. Mol. Biol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0081","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/oxfordjournals.annonc.a010490","article-title":"Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study","volume":"7","author":"Bisagni","year":"1996","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0082","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0960-0760(93)90245-R","article-title":"Structure-activity relationships and binding model of novel aromatase inhibitors","volume":"44","author":"Lang","year":"1993","journal-title":"J. Steroid. Biochem. Mol. Biol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0083","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2165\/00003495-199856060-00020","article-title":"Letrozole. A review of its use in postmenopausal women with advanced breast cancer","volume":"56","author":"Lamb","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/j.ctarc.2026.101134_bib0084","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1200\/JCO.2002.20.3.751","article-title":"Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study","volume":"20","author":"Geisler","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0085","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1200\/JCO.2007.14.4659","article-title":"Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group","volume":"26","author":"Paridaens","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0086","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1200\/JCO.2006.07.5382","article-title":"Aromatase inhibitors and bone health in women with breast cancer","volume":"24","author":"Chien","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0087","first-page":"2089","article-title":"In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients","volume":"4","author":"Geisler","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101134_bib0088","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1124\/dmd.110.032276","article-title":"In vitro cytochrome P450-mediated metabolism of exemestane","volume":"39","author":"Kamdem","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ctarc.2026.101134_bib0089","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00000421-199510000-00010","article-title":"Aromatase inhibitors: current status","volume":"18","author":"Ibrahim","year":"1995","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0090","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/FPC.0b013e32833b04af","article-title":"Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics","volume":"20","author":"Sun","year":"2010","journal-title":"Pharmacogenet. Genomics."},{"key":"10.1016\/j.ctarc.2026.101134_bib0091","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.313","article-title":"Exemestane potency is unchanged by common nonsynonymous polymorphisms in CYP19A1: results of a novel anti-aromatase activity assay examining exemestane and its derivatives","volume":"5","author":"Peterson","year":"2017","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.ctarc.2026.101134_bib0092","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.314","article-title":"In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17beta-dihydroexemestane","volume":"5","author":"Peterson","year":"2017","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.ctarc.2026.101134_bib0093","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/FPC.0000000000000226","article-title":"Impact of nonsynonymous single nucleotide polymorphisms on in-vitro metabolism of exemestane by hepatic cytosolic reductases","volume":"26","author":"Platt","year":"2016","journal-title":"Pharmacogenet. Genomics."},{"key":"10.1016\/j.ctarc.2026.101134_bib0094","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1158\/1535-7163.MCT-07-0312","article-title":"Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen","volume":"6","author":"Ariazi","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ctarc.2026.101134_bib0095","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0039-128X(93)90029-M","article-title":"Synthesis and aromatase inhibition by potential metabolites of exemestane (6-methylenandrosta-1,4-diene-3,17-dione)","volume":"58","author":"Buzzetti","year":"1993","journal-title":"Steroids."},{"key":"10.1016\/j.ctarc.2026.101134_bib0096","first-page":"5933","article-title":"Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women","volume":"52","author":"Evans","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101134_bib0097","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1749-6632.1990.tb34309.x","article-title":"Novel irreversible aromatase inhibitors","volume":"595","author":"di Salle","year":"1990","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ctarc.2026.101134_bib0098","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0925-4439(02)00096-0","article-title":"Exemestane, a new steroidal aromatase inhibitor of clinical relevance","volume":"1587","author":"Lombardi","year":"2002","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ctarc.2026.101134_bib0099","doi-asserted-by":"crossref","first-page":"10281","DOI":"10.1158\/0008-5472.CAN-06-2134","article-title":"Aromatase destabilizer: novel action of exemestane, a food and drug administration-approved aromatase inhibitor","volume":"66","author":"Wang","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101134_bib0100","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2165\/00003495-199958040-00007","volume":"58","author":"Scott","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.ctarc.2026.101134_bib0101","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/bjc.1995.451","article-title":"Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor","volume":"72","author":"Zilembo","year":"1995","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101134_bib0102","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1200\/JCO.22.00577","article-title":"Postoperative adjuvant anastrozole for 10 or 5 years in patients with hormone receptor-positive breast cancer: AERAS, a randomized multicenter open-label phase III trial","volume":"41","author":"Iwase","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0103","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1080\/14796694.2024.2377531","article-title":"The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer","volume":"20","author":"Fjermeros","year":"2024","journal-title":"Future Oncol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0104","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/ijc.34912","article-title":"Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: results from the open-label, multicentre, non-interventional BRAWO study","volume":"155","author":"Luftner","year":"2024","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101134_bib0105","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1007\/s12325-013-0060-1","article-title":"Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis","volume":"30","author":"Yardley","year":"2013","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ctarc.2026.101134_bib0106","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/ijc.31738","article-title":"Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: results of the single-arm, phase IIIB 4EVER trial","volume":"144","author":"Tesch","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101134_bib0107","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2217\/fon.12.49","article-title":"The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer","volume":"8","author":"Beaver","year":"2012","journal-title":"Future Oncol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0108","first-page":"255","article-title":"Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: a retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety","volume":"9","author":"Riccardi","year":"2018","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0109","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1021\/acs.jmedchem.2c01458","article-title":"Research progress on bioactive metal complexes against ER-positive advanced breast cancer","volume":"66","author":"Liang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ctarc.2026.101134_bib0110","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3816\/CBC.2005.n.006","article-title":"Aromatase inhibitors for the treatment and prevention of breast cancer","volume":"6","author":"Kalidas","year":"2005","journal-title":"Clin. Breast. Cancer"},{"key":"10.1016\/j.ctarc.2026.101134_bib0111","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s11033-021-06863-3","article-title":"Resistance to endocrine therapy in HR + and\/or HER2 + breast cancer: the most promising predictive biomarkers","volume":"49","author":"Miranda","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.ctarc.2026.101134_bib0112","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.amsu.2019.11.021","article-title":"Molecular classification of breast cancer: a retrospective cohort study","volume":"49","author":"FK","year":"2020","journal-title":"Ann. Med. Surg. (Lond)"},{"key":"10.1016\/j.ctarc.2026.101134_bib0113","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10549-018-5023-4","article-title":"Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals","volume":"173","author":"Szostakowska","year":"2019","journal-title":"Breast. Cancer Res. Treat."},{"key":"10.1016\/j.ctarc.2026.101134_bib0114","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.critrevonc.2019.05.001","article-title":"Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: current knowledge, new research directions and therapeutic perspectives","volume":"139","author":"Vernieri","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"Pt 3","key":"10.1016\/j.ctarc.2026.101134_bib0115","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.mce.2015.09.035","article-title":"Endocrine resistance in breast cancer\u2013an overview and update","volume":"418","author":"Clarke","year":"2015","journal-title":"Mol. Cell Endocrinol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0116","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nature13948","article-title":"Convergent loss of PTEN leads to clinical resistance to a PI(3)Kalpha inhibitor","volume":"518","author":"Juric","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ctarc.2026.101134_bib0117","article-title":"ESR1 alterations and metastasis in estrogen receptor positive breast cancer","volume":"5","author":"Lei","year":"2019","journal-title":"J. Cancer Metastasis Treat."},{"key":"10.1016\/j.ctarc.2026.101134_bib0118","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/10408363.2019.1670615","article-title":"The potential of ctDNA analysis in breast cancer","volume":"57","author":"Tzanikou","year":"2020","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/j.ctarc.2026.101134_bib0119","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1634\/theoncologist.2018-0314","article-title":"Exploring biomarkers of phosphoinositide 3-kinase pathway activation in the treatment of hormone receptor positive, Human epidermal growth receptor 2 negative advanced breast cancer","volume":"24","author":"Kaklamani","year":"2019","journal-title":"Oncologist."},{"key":"10.1016\/j.ctarc.2026.101134_bib0120","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13058-020-1246-5","article-title":"ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis","volume":"22","author":"Zundelevich","year":"2020","journal-title":"Breast. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101134_bib0121","doi-asserted-by":"crossref","first-page":"74448","DOI":"10.18632\/oncotarget.12950","article-title":"Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor","volume":"7","author":"Clatot","year":"2016","journal-title":"Oncotarget."},{"key":"10.1016\/j.ctarc.2026.101134_bib0122","first-page":"11","article-title":"The emerging role of ESR1 mutations in luminal breast cancer as a prognostic and predictive biomarker of response to endocrine therapy","author":"De Santo","year":"2019","journal-title":"Cancers. (Basel)"},{"key":"10.1016\/j.ctarc.2026.101134_bib0123","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.2147\/CMAR.S173193","article-title":"Clinical value of circulating ESR1 mutations for patients with metastatic breast cancer: a meta-analysis","volume":"10","author":"Zhang","year":"2018","journal-title":"Cancer Manage Res."},{"key":"10.1016\/j.ctarc.2026.101134_bib0124","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2501796","article-title":"Overall survival with Inavolisib in PIK3CA-mutated advanced breast cancer","volume":"393","author":"Jhaveri","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101134_bib0125","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrc3920","article-title":"Mechanisms of aromatase inhibitor resistance","volume":"15","author":"Ma","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ctarc.2026.101134_bib0126","doi-asserted-by":"crossref","first-page":"R283","DOI":"10.1530\/ERC-17-0425","article-title":"Acquired resistance to aromatase inhibitors: where we stand!","volume":"25","author":"Augusto","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.ctarc.2026.101134_bib0127","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13058-021-01462-3","article-title":"ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer","volume":"23","author":"Brett","year":"2021","journal-title":"Breast. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101134_bib0128","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11912-017-0591-8","article-title":"The evolving role of the estrogen receptor mutations in endocrine therapy-resistant breast cancer","volume":"19","author":"Jeselsohn","year":"2017","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ctarc.2026.101134_bib0129","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/ng.2822","article-title":"ESR1 ligand-binding domain mutations in hormone-resistant breast cancer","volume":"45","author":"Toy","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ctarc.2026.101134_bib0130","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13058-024-01843-4","article-title":"Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer","volume":"26","author":"Laine","year":"2024","journal-title":"Breast. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101134_bib0131","doi-asserted-by":"crossref","first-page":"15094","DOI":"10.1021\/acs.jmedchem.0c00913","article-title":"Selective estrogen receptor degraders (SERDs): a promising strategy for estrogen receptor positive endocrine-resistant breast cancer","volume":"63","author":"Lu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ctarc.2026.101134_bib0132","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40265-025-02266-x","article-title":"Imlunestrant: first approval","volume":"86","author":"Keam","year":"2026","journal-title":"Drugs"},{"key":"10.1016\/j.ctarc.2026.101134_bib0133","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-025-02168-6","article-title":"Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a\/1b EMBER study","author":"Bhave","year":"2025","journal-title":"Breast. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101134_bib0134","article-title":"Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial","author":"Jhaveri","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101134_bib0135","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.7150\/thno.69424","article-title":"Platinum-based drugs for cancer therapy and anti-tumor strategies","volume":"12","author":"Zhang","year":"2022","journal-title":"Theranostics."},{"key":"10.1016\/j.ctarc.2026.101134_bib0136","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1021\/cr980420v","article-title":"Current status of platinum-based antitumor drugs","volume":"99","author":"Wong","year":"1999","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ctarc.2026.101134_bib0137","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.2174\/092986712802002482","article-title":"Coinage metal complexes against breast cancer","volume":"19","author":"Biersack","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ctarc.2026.101134_bib0138","first-page":"36","article-title":"Advances in combination therapy for the treatment of estrogen receptor positive breast cancer","author":"Liu","year":"2025","journal-title":"Chinese Chem. Lett."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226000456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226000456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:44:59Z","timestamp":1780919099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226000456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":138,"alternative-id":["S2468294226000456"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101134","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of ER-positive breast cancer with FDA-approved aromatase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101134","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101134"}}